Peripheral T-cell Lymphomas

Current Classification and Differential Diagnosis

Elaine S Jaffe, M.D.
International T-cell Lymphoma Study: Frequency of Subtypes

Study limited to adults

JCO 2008;26:4124-4130
Overall Survival (%)

Time (years)

ALK+

ALK-

Anaplastic large cell lymphoma, ALK+
Anaplastic large cell lymphoma, ALK-
All natural killer/T-cell lymphomas
Peripheral T-cell lymphoma, not otherwise specified
Angioimmunoblastic lymphoma
Adult T-cell leukemia/lymphoma

P < .001

Vose et al. JCO 2008
Innate Immune System

- γδ T-cells, NK-like T-cells, NK-cells
- Toll like receptors
- Not MHC restricted
- Cytokines
- Chemokines
- Complement
- Apoptotic & necrotic cell death pathways
- First line of defense with a major role in barrier immunity

Adaptive Immune System

- B-cell
- T-cell
- Antigen presentation to T-cells in the context of MHC
- Ag specific receptors on B + T-cells
- Immunological defense characterized by specificity & memory
Innate Immune System

- γδ T-cells, NK-like T-cells, NK-cells

Adaptive Immune System

- T-cell

- Often cutaneous, mucosal, spleen & BM
- Cytotoxic
- Activated cells show frequent apoptosis, necrosis
- Includes most extranodal PTCLs, EBV+ T/NK cell lymphomas

- Lymphomas may relate to specific effector T-cells
- $T_{FH}$, Treg
- Functional consequences may be clinically apparent
- Includes most nodal PTCLs in adults
Peripheral T-cell Lymphoma, NOS

- A diagnosis of exclusion, by definition a heterogeneous category
- Characterized by a broad morphologic spectrum
  - New approaches include segregation of tumors of TFH origin (follicular variant)
  - Gene expression profiling recognizes tumors of TH1 and TH2 origin
- The “diffuse large B-cell lymphoma” of the PTLs
Subclassification of PTCL, NOS by gene expression

- **TBX21 / TBET (Th1)**
- **GATA3 (Th2)**
- Unclassifiable
Subclassification of PTCL, NOS: GATA3 & TBX21

Median OS (yrs)

- GATA3 0.9
- Unclassifiable 1.41
- TBX21 /TBET 2.08

TBX21/TBET (Th1 cells) - GATA3 (Th2 cells)
Angioimmunoblastic T-cell Lymphoma is a disease of germinal center derived T-cells (T_{FH} cell)

- CD3+
- CD10+
- BCL6 +/-
- CD279/PD-1+
- CXCL13 +

Increased B-cells - both EBV pos and neg

B-cells clonal in up to 50%
Perifollicular Localization of AITL T-cells
What is the utility of PD-1 immunostaining in differential diagnosis of AITL vs Reactive Hyperplasia?

Exercise caution – Intensity is key!
PD-1+ T-cells are invariably present in reactive paracortical hyperplasia
Reactive paracortical hyperplasia – 18 yo drug hypersensitivity
Strong PD-1 + cells in germinal center
Weak PD-1 in reactive paracortical T-cells
Nodal Peripheral T-cell Lymphomas of TFH origin

Angioimmunoblastic T-cell lymphoma

Follicular T-cell lymphoma

Nodal peripheral T-cell lymphoma with TFH phenotype

T-zone variant

TFH phenotype requires 2 or more TFH markers

Suggested panel:
PD1
ICOS
CD10
CXCL13
B-cell proliferations in AITL & TFH-PTCL

• EBV-positive
  – Variable numbers of EBV+ blasts, may be dominant picture
  – Hodgkin/Reed-Sternberg like cells

• EBV-negative
  – B-immunoblasts
  – Polyclonal plasma cells
  – Monotypic/ Monoclonal plasma calls
  – Hodgkin/Reed-Sternberg like cells
EBV neg B-cell proliferations in AITL and PTCL-TFH

Plasma cells
Often
Abundant
May be monoclonal & atypical

Balague et al.
Am J Surg Path 2007

CD20 + B-immunoblasts
TCR

IGH FR2

IGH FR3

Huppmann et al JCO 2012
Peripheral T-cell lymphoma with EBV+ HRS cells

T-cell population clonal,
Cytologically atypical
Usually has a TFH phenotype
“HRS-cells” are “B-lineage”

CD30

CD15

EBER
PTCL with HRS-like cells – An Update (57 cases)
Nicolae et al AJSP 2013

• PTCL classified as AITL, PTCL, often with $T_{FH}$ markers
• Intimate relationship between the HRS-like cells & neoplastic T-cells
• HRS-like cells
  – EBV-positive (52 cases)
  – EBV-negative (5 cases)
• Progression to classical Hodgkin’s lymphoma not observed
EBV-negative HRS like cells are also rosetted by neoplastic TFH cells
• AITL is characterized by proliferation and sometimes clonal expansion of B-cells, as well as neoplastic $T_{FH}$-cells
• Recent data indicate that B-cells may carry the same mutations as T-cells?
  – TET2 mutations identified in B-cells of patients with AITL (Schwartz FH J Pathol, 2017)
  – AITL may be a “stem cell” disease
Lymphomas of the Innate Immune System

- Often cutaneous, mucosal, spleen & BM
- Cytotoxic
- Activated cells show frequent apoptosis, necrosis
- Includes most pediatric T/NK neoplasms
Hepatosplenic T-cell lymphoma

- Most common in young males
- May be seen with chronic immune suppression
  - Crohn’s disease, pts treated with anti-TNF, 6-MP, Azathioprine
  - late occurring PTLD
- Hepatosplenomegaly, cytopenias, systemic symptoms; lack LN and PB involvement
- Aggressive behavior and dismal prognosis (<2y survival)
- Differential Dx: T-LGL in bone marrow, spleen
Recurrent Mutations in HSTCL

- **HSTCL**
  - STAT5B (33%); STAT3 (10%)
  - SETD2 (71%)

- **T-LGL**
  - STAT3 (40%); STAT5B (2%)

- **T-ALL**
  - JAK1, JAK3, STAT5B (subset)

- **T-PLL**
  - STAT5B (36%)
Subcutaneous Panniculitis-Like T-cell Lymphoma

CLINICAL FEATURES:
Broad age range (1 yr to 57 yrs) Median age - 30
Males = Females
Deep subcutaneous nodules
  primarily affecting extremities, trunk
Overall survival > 80% 5 years
Absence of nodal involvement
MORPHOLOGY:

Usually confined to subcutis, lobular distribution

Absence of dermal, epidermal involvement

– Helpful in distinction from cutaneous γδ T-cell lymphoma

Necrosis and karyorrhexis prominent

May show vascular invasion
Subcutaneous Panniculitis-like T-cell Lymphoma

**Immunophenotype & Genotype**

Activated $\alpha\beta$ T-cytotoxic phenotype

- CD3+, CD8+
- TIA-1+, Granzyme B+, Perforin +
- CD56 negative - *in contrast to* $\gamma\delta$
- EBV-negative
- TCR $\gamma/\beta$ genes rearranged
- Germline mutations in *HAVCR2* encoding TIM-3 in both Asian and European patients with HLH & SPTCL (Gayden et al. 2018)
Differential Diagnosis of SPTCL  
*Lupus profundus*

- Mixture of T-cells, B-cells, plasma cells
- Lobular pattern with preserved septa
- Fibrinoid change in connective tissue
- Interstitial infiltration, but infrequent rimming of fat spaces
- Mixture of CD4+/CD8+ cells
- Scattered gamma-delta T-cells
- Increased PDC’s (CD123+)
Subcutaneous Panniculitis-like TCL vs. Lupus profundus – Not always easy

- Oligoclonal T-cell populations can be seen in some patients with lupus, inclusive of the cutaneous lesions
- Correlate clinical, histological, and genetic features
- One should be cautious about making the diagnosis of SPTCL in a patient with lupus
Enteropathy Associated T-cell Lymphoma (EATL)

- Broad morphological spectrum
  - Adjacent mucosa shows villous atrophy
- CD3+, CD103+, Cytotoxic markers, TCR $\alpha\beta$
  - Often double negative for CD4/CD8
- Often presents with intestinal perforation
- Aggressive clinical course with poor prognosis
Enteropathy-associated T-Cell Lymphoma
[Classical form or Type I]

• Associated with celiac disease
  – 95% of patients have HLA-DQ2 and HLA-DQ8
  – Autoantibodies against tissue transglutaminase
  – Antibodies against gliadin
  – Gluten-free diet may reduce risk of lymphoma
Enteropathy Associated T-cell Lymphoma, Types I & II are distinct.

EATL I
Usually αβ
Celiac disease
N European

EATL II
Usually γδ
Epitheliotropic
Asian, Hispanic
Monomorphic epitheliotropic intestinal T-cell lymphoma (EATL II)

- Medium sized cells with clear cytoplasm
- CD56 +, CD8+, CD4-
- Usually gamma delta +
- MAT kinase +
- Mutations in STAT5B, JAK3, SETD2
JAK/STAT Pathway is an attractive target for therapy of Cytotoxic T-cell Lymphomas and Leukemias.
T-cell & NK cell Lymphomas of Gastrointestinal Tract

EATL
“Classical”
\[ \alpha\beta > \gamma\delta \]

MEITL
\[ \gamma\delta > \alpha\beta \]

Extranodal NK/T
EBV+ NK or T
Mainly Asian

PTCL, NOS
(\(\alpha\beta\) or \(\gamma\delta\) or
TCR silent

All clinically aggressive
All cytotoxic
Indolent T-cell lymphoproliferative disease of the GI tract (10 cases) (Perry et al. 2013)

- Ages 15-77 (median 48), M:F 6:4
- Oral cavity, stomach, small intestine, colon, esophagus
- Diarrhea, pain, rectal bleeding
  - “Crohn’s disease (2 patients), Colitis
- Follow-up: 9-175 months; Median 38 months
  - 2 pts followed >10 yrs, without progression
- 6 patients received chemotherapy for PTCL, with no response, but no progression
- Optimal therapy uncertain
Superficial infiltrate
Confined to mucosa
No invasion of the wall

Very low proliferation rate
No destruction of the glands
No cytological atypia
Very bland infiltrate

? Optimal management
Do not respond to chemorx
Indolent T-cell LPD of GI tract

Subset of cases are CD4+

- These may be more likely to progress to overt T-cell lymphoma
- Recurrent STAT3-JAK2 fusions in CD4+ cases but not in CD8+ cases (Sharma et al Blood 2018)

Prior reports published as

“Low grade intestinal T-cell lymphoma”

“Lymphomatous polyposis of T-cell type”

- Carbonnel 1994; Egawa 1995; Hirakawa 1996
- Margolskee 2013
NK-cell Enteropathy
An atypical proliferative lesion mimicking lymphoma

• 8 cases: M:F 1:3; Median age 49 (27-70)
• Vague GI symptoms, but negative for celiac disease
• Superficial lesions with hemorrhage, edema, ulceration
• Lesions in stomach, small intestine, and colon
• Indolent, relapsing clinical course without dissemination
  – Do not mistake for aggressive NK-cell lymphoma
Colon biopsy

CD56
Colon: Positive for cytoplasmic CD3, CD56, CD7; CD2+/-

Negative for CD5, CD4, CD8, EBER
Let’s switch gears ……
EVOLUTION OF ANAPLASTIC LARGE CELL LYMPHOMA, ALK+

Initial Description

HD → PTCL → MH

Immunophenotypic Studies

Ki-1+ Sinusoidal lymphoma

CD30+ EMA+ LCA+ CD15- CD3 -/+ 

Molecular Pathogenesis

Hallmark cells ALK+

Definition of Entity

t(2;5) NPM;ALK
ALCL

Bone marrow involvement

Scattered single cells in biopsy & smear

Adverse prognostic factor – best diagnosed with IHC of bone marrow
Translocations and fusion proteins involving ALK

<table>
<thead>
<tr>
<th>Translocation</th>
<th>Protein Fusion</th>
<th>Staining</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(2;5)</td>
<td>NPM/ALK</td>
<td>cytoplasmic/nuclear/nucleolar</td>
<td>70-80%</td>
</tr>
<tr>
<td>t(1;2)</td>
<td>TPM3/ALK</td>
<td>cytoplasmic</td>
<td>10-20%</td>
</tr>
<tr>
<td>t(2;3)</td>
<td>TFG/ALK</td>
<td>cytoplasmic</td>
<td>2-5%</td>
</tr>
<tr>
<td>Inv2</td>
<td>ATIC/ALK</td>
<td>cytoplasmic</td>
<td>2-5%</td>
</tr>
<tr>
<td>t(2;17)</td>
<td>CLTC/ALK</td>
<td>cytoplasmic/ granular</td>
<td>2-5%</td>
</tr>
<tr>
<td>t(2;19)</td>
<td>TPM4/ALK</td>
<td>cytoplasmic</td>
<td>1-2%</td>
</tr>
</tbody>
</table>
Histological Spectrum of ALCL, ALK+

• Anaplastic large cell lymphoma
  – Common
  – Lymphohistiocytic
  – Small cell

• Other histological patterns
  – Sarcomatoid appearance with myxoid stroma
  – Hypocellular with edematous background
Lymphohistiocytic variant of ALCL

CD30
Small Cell Variant of ALCL
Time to treatment failure curve according to the presence of a small-cell (SC) and/or lymphohistiocytic (LH) component (n = 361 patients).

Lamant L et al. JCO 2011;29:4669-4676
Genetic correlates with survival in ALCL, ALK+/ ALK-
Feldman et al. Blood 2014

- DUSP22 (# 22)
- ALK+ (# 32)
- ALK neg, no aberrations (#45)

Subset with DUSP22 R Comparable to ALK+
DUSP 22 Mutated ALCL has distinctive morphology and phenotype

Classical Hallmark cells

Granzyme B negative
<table>
<thead>
<tr>
<th>Leukemic/ Systemic</th>
<th>Extramodal</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-cell prolymphocytic leukaemia</td>
<td>Extranodal NK/T-cell lymphoma, nasal type</td>
</tr>
<tr>
<td>T-cell large granular lymphocytic leukaemia</td>
<td>Enteropathy-associated T-cell lymphoma</td>
</tr>
<tr>
<td>Chronic lymphoproliferative disorder of NK cells</td>
<td>Monomorphie epitheliotropic intestinal T-cell lymphoma</td>
</tr>
<tr>
<td>Aggressive NK cell leukaemia</td>
<td>Indolent T-cell lymphoproliferative disorder of the GI tract</td>
</tr>
<tr>
<td>Systemic EBV+ T-cell Lymphoma of childhood</td>
<td>Breast implant-associated anaplastic large cell lymphoma</td>
</tr>
<tr>
<td>Hydroa vacciniforme-like lymphoproliferative disorder</td>
<td></td>
</tr>
<tr>
<td>Adult T-cell leukaemia/lymphoma</td>
<td></td>
</tr>
<tr>
<td>Hepatosplenic T-cell lymphoma</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cutaneous</th>
<th>Nodal/ Extramodal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous panniculitis- like T-cell lymphoma</td>
<td>Peripheral T-cell lymphoma, NOS</td>
</tr>
<tr>
<td>Mycosis fungoides/ Sézary syndrome</td>
<td>Angioimmunoblastic T-cell lymphoma</td>
</tr>
<tr>
<td>Primary cutaneous CD30 positive T-cell lymphoproliferative disorders</td>
<td>Follicular T-cell lymphoma</td>
</tr>
<tr>
<td>- Lymphomatoid papulosis</td>
<td>Nodal peripheral T-cell lymphoma with TFH phenotype</td>
</tr>
<tr>
<td>- Primary cutaneous anaplastic large cell lymphoma</td>
<td>Anaplastic large cell lymphoma, ALK positive</td>
</tr>
<tr>
<td>Primary cutaneous gamma-delta T-cell lymphoma</td>
<td>Anaplastic large cell lymphoma, ALK negative</td>
</tr>
<tr>
<td>Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma</td>
<td></td>
</tr>
<tr>
<td>Primary cutaneous acral CD8+ T-cell lymphoma</td>
<td></td>
</tr>
<tr>
<td>Primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder</td>
<td></td>
</tr>
</tbody>
</table>